Research Topics
| TIMOTHY CRIPESummaryAffiliation: Cincinnati Children's Hospital Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progressBalveen Kaur
Dardinger Laboratory for Neuro oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio, USA
Curr Pharm Biotechnol 13:1842-51. 2012..We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy...
Targeting cancer-initiating cells with oncolytic virusesTimothy P Cripe
Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA
Mol Ther 17:1677-82. 2009..Here we review the available data regarding the ability of several different oncolytic virus types to target CICs for destruction...- Can less really be more? Using lessons from leukemia and cancer stem cells to make sense of oral maintenance for metastatic sarcomaTimothy P Cripe
Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, Ohio 45229, USA
Pediatr Blood Cancer 50:737-8. 2008 - Promoting translational research in academic health centers: navigating the "roadmap"Timothy P Cripe
Division of Hematology Oncology, MLC R7015, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Acad Med 80:1012-8. 2005..The broad success of this program suggests that it might serve as a model for other academic health centers in promoting and conducting translational research... - Improving patient care: the use of a digital teaching file to enhance clinicians' access to the intellectual capital of interdepartmental conferencesMark J Halsted
Department of Radiology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3039, USA
AJR Am J Roentgenol 182:307-9. 2004..This system improves the efficiency and accuracy in gathering patient histories when care is transferred among clinics, the emergency department, and wards... 
Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C proteinXiaoyang Qi
Division and Program in HumanGenetics, 3333 Burnet Avenue, Cincinnati, Ohio 45229 3039, USA
Clin Cancer Res 15:5840-51. 2009..We investigated the antitumor efficacy and systemic biodistribution of nanovesicles comprised of saposin C coupled with dioleoylphosphatidylserine in preclinical cancer models...- Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumorsGunnar Johansson
Division of Experimental Hematology, University of Cincinnati, Cincinnati, OH, USA
Mol Cancer Ther 7:1237-45. 2008..The preclinical tests described allow rapid screening strata for drugs that block MPNST growth, prior to tests in more complex models, and should be useful to identify drugs that synergize with RAD001... - Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumorsArturo R Maldonado
Division of Pediatric General and Thoracic Surgery, The Center for Molecular Fetal Therapy, Children s Hospital Medical Center, Cincinnati, OH, USA
J Gene Med 12:613-23. 2010..In the present study, we sought to leverage its selective expression to develop a novel oncolytic herpes simplex virus (oHSV) capable of targeting developmentally primitive cancers that express MDK... - Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virusYonatan Y Mahller
Division of Hematology and Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States of America
PLoS ONE 4:e4235. 2009..Based on cues from normal stem cells, evidence for tumor populating progenitor cells has been found in a variety of cancers... - Cyclooxygenase-2 expression in pediatric sarcomasDavid S Dickens
Department of Pediatrics, Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Pediatr Dev Pathol 5:356-64. 2002..We conclude that the majority of these pediatric sarcoma samples express COX-2 to varying degrees. Therefore, studies testing the efficacy of COX-2 inhibitors in the treatment of pediatric sarcomas are warranted... - Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitorsYonatan Y Mahller
Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Cancer Res 68:1170-9. 2008..These findings support the further development of combined TIMP-3 and oncolytic virotherapy for cancer... - Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcomaDavid S Dickens
Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
J Pediatr Hematol Oncol 25:282-5. 2003..However, COX-2 inhibitors are not entirely dependent upon enzyme expression for their antitumor effects; this study does not necessarily preclude the use of COX-2 inhibitors for the treatment of pediatric sarcomas... - Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical modelsNehal S Parikh
Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Pediatr Blood Cancer 44:469-78. 2005..CONCLUSIONS: Nb tumor models are resistant to adenovirus mediated oncolysis but highly sensitive to HSV mediated oncolysis. Further studies of HSV virotherapy as a novel treatment for Nb are warranted... - Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciencesChunyan Liu
Division of Biostatistics and Epidemiology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Mol Ther 18:1724-30. 2010..We recommend resampling as a method that readily adjusts the post hoc testing to be limited to only interesting comparisons and thereby avoids unduly sacrificing the power... - Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex virusesMark A Currier
Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Cancer Gene Ther 12:407-16. 2005..Therefore, strategies to maximize intratumoral virus distribution at initial delivery should be sought... - Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex virusesNeeti S Bharatan
Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA
J Pediatr Hematol Oncol 24:447-53. 2002.... - Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivoTrisha M Wise-Draper
Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Cancer Res 69:1792-9. 2009..Taken together, our data uncover oncogenic DEK activities as postulated from its frequent up-regulation in human malignancies, and suggest that the targeted suppression of DEK may become a strategic approach to the treatment of cancer... - Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutantsYonatan Y Mahller
Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Pediatr Blood Cancer 46:745-54. 2006..Virus-induced cytotoxicity of MPNST cell lines was caused by both direct lysis and apoptosis. Our data suggest the use of oncolytic HSV mutants may represent a novel treatment approach for patients with MPNSTs... - Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenograftsDavid S Dickens
Division of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Ohio 45229, USA
J Pediatr Hematol Oncol 25:709-14. 2003..CONCLUSIONS: The authors' preclinical data suggest that the combination of inexpensive, nontoxic, oral COX-2 and MMP inhibitors may be useful for the treatment of some types of solid tumors... - Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft modelYonatan Y Mahller
Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
Mol Ther 15:279-86. 2007..Overall, oHSVs showed highly potent antitumor effects against MPNST xenografts, an effect not diminished by EGFR inhibition. Our data suggest that inclusion of MPNSTs in clinical trials of oHSV is warranted... - Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamideMark A Currier
Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Mol Ther 16:879-85. 2008..HSV replication was not detected in reactivation studies of isolated organs. Our findings suggest rRp450/CPA is safe and warrants further study as a potential combination in anticancer therapeutics...
Research Grants
- Oncolytic HSV Therapy in Immunocompetent Sarcoma ModelsTIMOTHY CRIPE; Fiscal Year: 2007..Our results will guide the design of future clinical trials using these novel agents. ..
- Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors,IND 13196 12/04/2006Timothy P Cripe; Fiscal Year: 2010..Because nonclinical data suggest systemic delivery of the virus may also have therapeutic benefit for metastases, this study may also enable future trials of systemic HSV1716. ..
- Oncolytic HSV Therapy in Immunocompetent Sarcoma ModelsTimothy P Cripe; Fiscal Year: 2010..Our results will guide the design of future clinical trials using these novel agents. ..